Investors & Media
What’s new.


Press releases
Press releases.
April 29th 2025
Immutep Quarterly Activities Report Q3 FY25
Investor updates
Analyst reports
Analyst reports.
May 16th 2025
Maxim - Positive Response Data from INSIGHT-003 in 1L NSCLC; Bodes Well for Ongoing P3 Pivotal TACTI-004 Study - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)
May 15th 2025
Baird - New IST Data for Triple Combo Further Supportive of Potential in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)
May 15th 2025